No Data
Express News | Vertex Pharmaceuticals: Safety Profile of Casgevy in Children Is Consistent With Myeloablative Conditioning, Autologous Transplant in Scd & Tdt
Express News | Vertex Pharmaceuticals: Presents New Data on Casgevy, Including First-Ever Data in Children Ages 5-11 Years
Express News | Vertex Pharmaceuticals: Expects to Initiate Global Regulatory Submissions for Casgevy in Children 5-11 Years in 1H 2026
Express News | Vertex: Consistent With Studies in Older Patients, Children Treated With Casgevy Have Durable Increases in Fetal Hemoglobin & Stable Allelic Editing
Vertex Pharmaceuticals(VRTX.US) Officer Sells US$6.38 Million in Common Stock
$Vertex Pharmaceuticals(VRTX.US)$ Officer WAGNER CHARLES F JR sold 14,000 shares of common stock on Dec 3, 2025 at an average price of $456 for a total value of $6.38 million.Source: Announcement
Vertex Pharmaceuticals(VRTX.US) Officer Sells US$28.65 Million in Common Stock
$Vertex Pharmaceuticals(VRTX.US)$ Officer LEIDEN JEFFREY M sold 63,781 shares of common stock on Dec 3, 2025 at an average price of $449.2 for a total value of $28.65 million.Source: Announcement